Biotech: A Strategic Industry, If We Can Keep It What is clearly lacking right now, and what it is incumbent on industry itself to develop, is an exciting, compelling vision for America’s continued dominance in medical innovation.
10:00-10:55 am – 12th Floor
Spotlight Panel 1A
BioFuture Now: Breakthroughs Shaping the Next Era of Biopharma Trailblazers From the newest in molecular medicines and AI native discovery engines to connected medtech and platform companies— discuss what will be next across the life sciences. This group will highlight technologies that cut across oncology, CNS, metabolic disease, diagnostics, and beyond.
10:00-10:55 am – Roof
Spotlight Panel 1B
Immunity Unleashed: Next-Gen Therapies & Immune Engineering The immune companies to watch. Leaders in next-gen cell therapy, immune engineering, and precision immunomodulation reveal how they’re creating safer, scalable, and differentiated therapies—and where the biggest opportunities lie for investors and pharma.
11:00-11:55 am– 12th Floor
Spotlight Panel 2A
Molecules & Machine Learning: The AI Drug Discovery Frontier Hear from CEOs building AI-first platforms for target discovery, molecule design, and smarter R&D. Learn how AI is accelerating drug development, improving portfolio decisions, and creating the next generation of biotech value.
11:00-11:55 am – Roof
Spotlight Panel 2B
Healthspan Horizons: Advancing Longevity Therapeutics Companies reimagining what it means to extend healthy human life, highlighting breakthrough platforms in cellular rejuvenation, metabolic optimization, and age‑related disease prevention, with a focus on improving outcomes and prognosis for diseases of aging.
12:00-1:00 pm – 2nd Floor
Networking Lunch
1:00 pm – 2nd Floor
One-to-One Meetings
1:00-1:55 pm – Roof
“Big Think" Plenary Session
Healthcare in the US: A Difficult Discussion We Need to Have This sector is all about developing and bringing new treatments to patients in need. Teams put everything on the line in the hope that an asset will succeed in clinical trials and receive approval. But, in the US, where we pay the highest per capita cost for healthcare yet receive the lowest benefit of all the OECD counties, access to healthcare is not at all guaranteed for a variety of reasons. We need to affect change. And to do that, we need to discuss what change we want.
2:00-2:55 pm – 12th Floor
Spotlight Panel 3A
Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics Biotech CEOs redefining oncology on multiple frontiers will explore next generation cell therapies, AI enabled cancer drug discovery, and highly personalized oncology approaches powered by precision medicines and advanced platforms.
2:00-2:55 pm – Roof
Spotlight Panel 3B
Where Technology & Code Meet Cells: Forging the MedTech & TechBio Future Companies building at the live interface of hardware, software, and biology will explore AI powered diagnostics, connected and implantable devices, programmable biology, and data driven care platforms that are redefining how we detect, treat, and optimize health.
3:00-3:55 pm – 12th Floor
Dialogue 1A
AI & Deep Tech in Drug Discovery: Will it Cut the 90% Problem Artificial intelligence and deep tech in drug discovery have successfully compressed preclinical timelines from years to months and boosted Phase I safety success rates, but they have not yet fundamentally solved the overarching 85% to 90% clinical failure rate in human efficacy trials – yet.
4:00-4:55 pm – Roof
End of Day “Big Think" Plenary Session
Funding Is Coming Back: But Who Is Getting Funded? Biotech financing has entered a new era. While capital is slowly returning to the sector, it is flowing selectively. This session will explore how today’s biotech leaders are navigating a more disciplined investment environment and what it takes to secure funding in the current market.